Chemical formula: C₄₁H₆₄O₁₄ Molecular mass: 780.939 g/mol PubChem compound: 2724385
Digoxin is indicated for:
Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)
Digoxin is indicated in the management of chronic cardiac failure where the dominant problem is systolic dysfunction. The therapeutic benefit of digoxin is greater in patients with ventricular dilatation.
Digoxin is specifically indicated where cardiac failure is accompanied by atrial fibrillation.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only newborns (0 - 40 days old) , infants (40 days - 1 year old) , children (1 year - 12 years old)
Digoxin is indicated in the management of chronic cardiac failure where the dominant problem is systolic dysfunction. The therapeutic benefit of digoxin is greater in patients with ventricular dilatation.
Digoxin is specifically indicated where cardiac failure is accompanied by atrial fibrillation.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)
Digoxin is indicated in the management of certain supraventricular arrhythmias, particularly chronic atrial fibrillation and flutter, where its major beneficial effect is to reduce the ventricular rate.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)
Digoxin is indicated in the management of certain supraventricular arrhythmias, particularly chronic atrial fibrillation and flutter, where its major beneficial effect is to reduce the ventricular rate.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only newborns (0 - 40 days old) , infants (40 days - 1 year old) , children (1 year - 12 years old)
Digoxin is indicated in the management of certain supraventricular arrhythmias, particularly chronic atrial fibrillation and flutter, where its major beneficial effect is to reduce the ventricular rate.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only newborns (0 - 40 days old) , infants (40 days - 1 year old) , children (1 year - 12 years old)
Digoxin is indicated in the management of certain supraventricular arrhythmias, particularly chronic atrial fibrillation and flutter, where its major beneficial effect is to reduce the ventricular rate.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Digoxin is contraindicated in the following cases:
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
